ISMICS, Los Angeles, USAMay 30 - June 2
Specifically designed for cardiovascular surgery.
Read more >>>
Oslo, April 25th, 2012 Medistim received confirmation from Canada Health that the company's new product VeriQ C is cleared for sale in Canada.
Findings substantiate the VeriQ system’s ability to improve outcomes for coronary artery bypass surgery and contain costs.
“The VeriQ system is associated with an estimated cost saving of £115 per patient compared with clinical assessment, when it is used routinely for assessing coronary artery bypass grafts during surgery.”